Square
Pharmaceuticals Ltd.
Square
Pharmaceuticals Ltd. was established as a partnership firm in 1958. In 1991 it
was converted into a public limited company. Square Pharmaceuticals Limited is
the largest pharmaceutical company in Bangladesh and it has been continuously
in the 1st position among all national and multinational
companies since 1985. Since 1987 Square has taken aggressive measures to
explore new countries as potential export market. More & more countries are
getting confidence in Square’s product every year. But it’s true that in the
competitive global environment Square is still struggling to ensure firm
footings in global market. Square is the flagship Pharma Company in Bangladesh,
wants to be a global player. As recognition to its export contribution to
national economy, Square received the National Export Trophy in 1997. To
strengthen it’s global operation further, Square is planning to enter in
Russian Pharma market considering market potentiality.
The Competitive Advantage of Square Pharmaceuticals Ltd.
SQUARE PHARMA is one of the leading companies in the
pharmaceutical industry of the country and could attain almost 15% of the local
market. The strength of attaining such position in the industry are:
Brand
Leadership
As survey showed that 27 of SQUARE PHARMA’s products are
found to be brand leaders out of 47 products surveyed while 10 stand at second
place.
Market
Recognition
Beximco has secured market recognition in the market
through innovative marketing strategies and aggressive product promotion. The
company’s strong support to the medical community has gained its brand loyalty
from the doctors.
Market Growth
The market is expected to grow by 15 to 20% per annum for
the next 5 years. The compounded annual growth for the previous 6 years was
15%. The next stage of growth is expected to come from backward integration to
manufacture high volume raw materials, introduction of Hi-Tech manufacturing
process that are difficult to imitate products, and exports.
Aggressive
Diversification
SQUARE PHARMA is keen to diversify its capacity of
produce and market. Strong export demand and international product registration
have led SQUARE PHARMA to embark on a massive capacity expansion as evident in
expansion of plant and establishment of new plant in compliance with FDA
(Federal Drug Association) quality mark .
Recently SQUARE PHARMA signed a new contract for loan of
about 1100 million BDT for its FDA (Federal drug Administration) compliant
plant that costs over BDT 3,000 million BDT.
Basic
Chemicals and Multipurpose Chemical Plant
Currently bulk antibiotics amoxycillin, ampicillin, and
cloxacillin are being produced with an installed capacity of 35 tons per month.
It is going to introduced Cephalexin and Cephradine very soon; like-wise in its
multi purpose unit, production of Amlodipine, Fluconazole, Clotrimazole,
Cetirizine Hcl, Tramadol, and Riboflavin 5-phosphate sodium.
Opportunities
There are some of the sectors where SQUARE PHARMA has not
entered but that possess ample opportunities. One of such sector is SVP or
small volume Parenteral that is known as injections in the market. Due to
having the quality attainment capability as evident in producing IV products,
expertise and resource SQUARE PHARMA should immediately think of this product
and decide upon having the feasibility study.
International market is also another very lucrative
sector for SQUARE PHARMA. In the world market the low cost of product is an
important upper hand for SQUARE PHARMA to market its product. The new FDA
compliant plant will assist SQUARE PHARMA to confirm the world market about the
quality of its products.
